Ramon Roca

Dr. Ramon Roca

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2018 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
MDMarije Van Doorn
Marije Van Doorn
AHAnnemien Haveman-Nies
Annemien Haveman-Nies
PPP. Pilichowski
P. Pilichowski
RRRamon Roca
Ramon Roca
JVJ. H. M. de Vries
J. H. M. de Vries
CGCornelia De Groot
Cornelia De Groot
A good nutritional status is key for maintaining health and quality of life in older adults. In the Netherlands, 11 to 35% of the community-dwelling elderly are undernourished. Undernutrition or the risk of it should be signalled as soon as possible to be able to intervene at an early stage. However, in the context of an ageing population health care resources are scarce, evoking interest in health enabling technologies such as telemonitoring. This article describes the design of an intervention study focussing at telemonitoring and improving nutritional status of community-dwelling elderly. The PhysioDom Home Dietary Intake Monitoring intervention was evaluated using a parallel arm pre-test post-test design including 215 Dutch community-dwelling elderly aged > 65 years. The six-month intervention included nutritional telemonitoring, television messages, and dietary advice by a nurse or a dietician. The control group received usual care. Measurements were performed at baseline, after 4.5 months, and at the end of the study, and included the primary outcome nutritional status and secondary outcomes behavioural determinants, diet quality, appetite, body weight, physical activity, physical functioning, and quality of life. Furthermore, a process evaluation was conducted to provide insight into intervention delivery, feasibility, and acceptability. This study will improve insight into feasibility and effectiveness of telemonitoring of nutritional parameters in community-dwelling elderly. This will provide relevant insights for health care professionals, researchers, and policy makers. The study was retrospectively registered at Clinical-Trials.gov (identifier NCT03240094 ) since August 3, 2017.

26 August 2025 in Vaccines
Verified
Journal Article
Open access
AAAntonio Arévalo-Genicio
Antonio Arévalo-Genicio
MGMª Carmen García-Arqué
Mª Carmen García-Arqué
MGMarta Gragea-Nocete
Marta Gragea-Nocete
MLMaria Llistosella
Maria Llistosella
VMVanessa Moro-Casasola
Vanessa Moro-Casasola
RRRamon Roca
Ramon Roca
Background: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of long COVID in association with the number of infections and vaccination status. Methods: We analyzed anonymized data on long COVID cases, thrombotic events and polypharmacy from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we analyzed responses to a long COVID symptom-specific survey distributed in March 2024 to individuals aged 18 to 75 years from the CST population diagnosed with COVID-19 as of December 2023 (n = 43,398; 3227 respondents). Symptomatic patients suspected of having long COVID underwent blood tests to exclude alternative diagnoses. Results: The overall detected prevalence of long COVID was 2.4‰, with higher frequency among women aged 30–59 years (p < 0.001). The survey, combined with specific blood tests, improved detection rates by 26.3%. Long COVID prevalence was 3–10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events among individuals aged >60 doubled from 2020 to 2024, occurring in both vaccinated and unvaccinated individuals, as well as in those with or without prior documented COVID-19 infection, including in patients without chronic treatments. Conclusions: We found a link between SARS-CoV-2 reinfection and long COVID, and a post-pandemic rise in thrombotic events across all populations, regardless of vaccination or prior infection. Findings support continued COVID-19 diagnosis in suspected cases and mask use by healthcare workers treating respiratory patients.

4 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
AAAntonio Arévalo-Genicio
Antonio Arévalo-Genicio
CGCarmen García-Arqué
Carmen García-Arqué
MGMarta Gragea-Nocete
Marta Gragea-Nocete
MLMaria Llistosella
Maria Llistosella
VMVanesa Moro-Casasola
Vanesa Moro-Casasola
RRRamon Roca
Ramon Roca
BACKGROUND: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of Long COVID in association with the number of infections and vaccination status. METHODS: We analyzed anonymized data on Long COVID cases and thrombotic events from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we evaluated responses from a specific Long COVID symptom survey distributed to the entire CST population (n=1871 respondents). Symptomatic patients suspected of having Long COVID underwent blood tests to exclude alternative diagnoses. RESULTS: The overall detected prevalence of Long COVID was 2.4‰, with higher frequency among women aged 30–59 years. The survey, combined with blood test, improved detection rates by 26.3%. Long COVID prevalence was 3-10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events doubled from 2020 to 2024 (p<0.0000001), occurring in both vaccinated and unvaccinated individuals, as well as in those with prior COVID-19 infection. CONCLUSION: Our findings demonstrate a link between SARS-CoV-2 reinfection and Long COVID prevalence. Furthermore, we observed a significant post-pandemic increase in thrombotic events across all populations, regardless of vaccination status or documented prior COVID-19 infection. Results suggest that COVID diagnosis should continue in suspected cases and that healthcare workers attending respiratory patients should continue wearing protective masks.

2 February 2026 in Viruses
Verified
Journal Article
Open access
PDF file
APAnna Puigdellívol-Sánchez
Anna Puigdellívol-Sánchez
AAAntonio Arévalo-Genicio
Antonio Arévalo-Genicio
MGMª Carmen García-Arqué
Mª Carmen García-Arqué
MGMarta Gragea-Nocete
Marta Gragea-Nocete
CLCelia Lozano-Paz
Celia Lozano-Paz
MLMaria Llistosella
Maria Llistosella
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations during the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines had significantly reduced hospital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine prescription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n = 192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive infections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihistamine users with at least one chronic prescription (p < 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.

19 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
APAnna Puigdellívol-Sánchez
Anna Puigdellívol-Sánchez
AAAntonio Arévalo-Genicio
Antonio Arévalo-Genicio
MGM. Carmen García-Arqué
M. Carmen García-Arqué
MGMarta Gragea-Nocete
Marta Gragea-Nocete
CLCelia Lozano-Paz
Celia Lozano-Paz
MLMaria Llistosella
Maria Llistosella
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations dur-ing the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines significantly reduced hos-pital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine pre-scription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n=192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive in-fections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihista-mine users with at least one chronic prescription (p< 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.

25 March 2026 in Health Psychology Review
Verified
Journal Article
Closed access
CGCristina Garriga-Salvó
Cristina Garriga-Salvó
ENEmiliano Navarro
Emiliano Navarro
Cristina Lidón-MoyanoCristina Lidón-Moyano
Cristina Lidón-Moyano
AAAntonio Arévalo
Antonio Arévalo
RRRamon Roca
Ramon Roca
MLMaria Llistosella
Maria Llistosella
Introduction: Long COVID involves a variety of persistent symptoms after initial SARS-CoV-2 infection, affects multiple functional areas and requires multidisciplinary treatment. Objective: This study aimed to explore the available evidence about psychological interventions for individuals with long COVID and their effectiveness in reducing some prevalent symptoms, such as fatigue, anxiety or depression, among others, and improving patient quality of life. Methodology: A systematic review and meta-analysis were conducted following the PRISMA 2020 guidelines. Two independent reviewers performed study selection and data extraction using Web of Science, Scopus, and PubMed databases prior to March 2024. Data synthesis was performed via random-effects meta-analysis, with heterogeneity assessed using the I2 statistic. Results: Of the 1041 articles obtained, 19 were included in the systematic review and 14 in the meta-analysis. Results showed significant reductions in symptoms of anxiety [SMD = -0.64 (95% CI: -1.18 to -0.10)], depression [SMD = -0.41 (95% CI: -0.73 to -0.10)] and fatigue [SMD = -1.37 (95% CI: -2.48 to -0.26)]. Significant improvements were only registered in self-perceived health-related quality of life [SMD = 7.59 (95% CI: 3.70-11.48)]. Conclusion: Results showed improvements in anxiety, depression or fatigue, highlighting the potential role of psychological interventions in patient recovery.